No substitute.

Among 65 new oncology drugs approved in the US between 2011-2017, three-quarters were approved based on survival “surrogate” endpoints and half have still failed to prove any benefit in either survival or even patient-reported outcomes. | Zettler, JAMA Oncol 2019